Groundbreaking Immunotherapy Shows Promise Against Metastatic Cancer
A class of immunotherapies called CD40 agonist antibodies has been under development for 20 years, but has shown limited success in clinical trials. However, a new study published in Cancer Cell presents promising results for a specific antibody, 2141.V11, which was engineered to improve efficacy and reduce side effects. Researchers at Rockefeller University’s Jeffrey V. … Read more